Trajectories of individual symptoms in remitters versus non-remitters with depression

Sakurai, Hitoshi; Uchida, Hiroyuki; Abe, Takayuki; Nakajima, Shinichiro; Suzuki, Takefumi; Pollock, Bruce G.; Sato, Yuji; Mimura, Masaru

doi:10.1016/j.jad.2013.06.035

Cited by 43 publications

(50 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also analysed the prediction of remission (at week 8) using early improvement of each HAM-D17 item, partly to compare with the previous study by Sakurai et al (2013) (Supplementary Fig. 2A).…”

Section: Predictor Analysis: Prediction Of Remission Using Early Imprmentioning

confidence: 99%

“…by Sakurai et al (2013) who found that sad mood and involvement, as assessed by QIDS-SR16 and QIDS-C16, showed major changes in 14-week treatment. Thus, those core symptoms could be important indicators to evaluate the treatment outcomes.…”

Section: Trajectory Of Symptom Improvement In Remitters and Nonremittersmentioning

confidence: 99%

“…However, these studies did not focus on the differences in trajectories among different depression symptoms. Recently, Sakurai et al (2013) demonstrated that depression symptoms show improvement with citalopram treatment over time in both remitters and nonremitters, as measured using the QIDS-SR16 and QIDS-C16. Our data support that finding, though with a different treatment (DLX) and using a different scale (the HAM-D17) to measure symptom improvement.…”

Section: Trajectory Of Symptom Improvement In Remitters and Nonremittersmentioning

confidence: 99%

“…For example, responses on some items could improve faster or better than others in remitters, but not in nonremitters. Trajectories of individual symptoms in remitters and nonremitters were examined by secondary analysis of the STAR*D trial data (Sakurai et al, 2013). In that study, patients were treated with citalopram, and symptoms were evaluated using the16-item Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR16) and the 16-item Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C16) versions.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials

Tokuoka

Takahashi

Ozeki

et al. 2016

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

Section: Predictor Analysis: Prediction Of Remission Using Early Imprmentioning

confidence: 99%

Section: Trajectory Of Symptom Improvement In Remitters and Nonremittersmentioning

confidence: 99%

Section: Trajectory Of Symptom Improvement In Remitters and Nonremittersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials

Tokuoka

Takahashi

Ozeki

et al. 2016

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

“…For example, Sakurai et al examined whether trajectories of individual depressive symptoms over time could predict remission in the acute phase in MDD by analyzing the data from the Sequenced Treatment Alternatives to Relieve Depression study. 11 They noted that improvements with citalopram in sad mood, low energy, feeling slowed down, restlessness, and negative self-view in week 2 were associated with remission in week 14. We are unaware of another report that has examined trajectories in specific depressive symptoms or symptom clusters to effectively predict remission in MDD.…”

mentioning

confidence: 99%

Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine

Funaki

Nakajima

Suzuki

et al. 2016

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Few studies, to our knowledge, have examined whether early improvements in individual, instead of overall, depressive symptoms predict remission in major depressive disorder (MDD). This post hoc analysis used data from 194 patients with MDD enrolled in a 6-week double-blind, placebo-controlled, randomized trial of mirtazapine, to identify improvements in specific individual depressive symptoms in the early phase that are associated with subsequent remission. Trajectories of individual depressive symptoms over 6 weeks were compared between remitters and nonremitters. Early improvement was defined as a ≥20% decrease in the Hamilton Rating Scale for Depression 17 items (HAM-D17) total score in weeks 1 and 2, and remission was defined as a HAM-D17 final score of ≤7. Reliability parameters were calculated for early improvements in predicting later remission. Whether improvement in each of the HAM-D17 symptoms in weeks 1 or 2 predicted remission was examined, using binary logistic regression analyses. As a result, improvements in weeks 1 and 2 were associated with sensitivity of 0.82 and 0.99 and specificity of 0.54 and 0.44, respectively, in predicting remission in week 6. Improvements in insomnia late (P = .04) and insight (P = .007) in week 1 and somatic symptoms general (P = .002) and insight (P = .04) in week 2 were associated with remission in week 6. In conclusion, early improvements in insight, insomnia late, and somatic symptoms general, as well as overall depressive symptoms, may serve as specific clinical indicators of subsequent remission in patients with MDD receiving mirtazapine.

show abstract

Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults

et al. 2015

View full text Add to dashboard Cite

IMPORTANCE More than 50% of older adults with late-life major depressive disorder fail to respond to initial treatment with first-line pharmacological therapy. OBJECTIVES To assess typical patterns of response to an open-label trial of extended-release venlafaxine hydrochloride (venlafaxine XR) for late-life depression and to evaluate which clinical factors are associated with the identified longitudinal response patterns. DESIGN, SETTING, AND PARTICIPANTS Group-based trajectory modeling was applied to data from a 12-week open-label pharmacological trial conducted in specialty care as part of the Incomplete Response in Late Life: Getting to Remission Study. Clinical prognostic factors, including domain-specific cognitive performance and individual depression symptoms, were examined in relation to response trajectories. Participants included 453 adults aged 60 years or older with current major depressive disorder. The study was conducted between August 2009 and August 2014. INTERVENTION Open-label venlafaxine XR (titrated up to 300 mg/d) for 12 weeks.MAIN OUTCOMES AND MEASURES Subgroups exhibiting similar response patterns were derived from repeated measures of overall depression severity obtained using the Montgomery-Asberg Depression Rating Scale.RESULTS Among the 453 study participants, 3 subgroups with differing baseline depression severity clearly responded to treatment: one group with the lowest baseline severity had a rapid response (n = 69 [15.23%]), and distinct responses were also apparent among groups starting at moderate (n = 108 [23.84%]) and higher (n = 25 [5.52%]) baseline symptom levels. Three subgroups had nonresponding trajectories: 2 with high baseline symptom levels (totaling 35.98%: high, nonresponse 1, n = 110 [24.28%]; high, nonresponse 2, n = 53 [11.70%]) and 1 with moderate baseline symptom levels (n = 88 [19.43%]). Several factors were independently associated with having a nonresponsive trajectory, including greater baseline depression severity, longer episode duration, less subjective sleep loss, more guilt, and more work/activity impairment (P < .05). Higher delayed memory (list recognition) performance was independently associated with having a rapid response (adjusted odds ratio = 2.22; 95% CI, 1.18-4.20). CONCLUSIONS AND RELEVANCEBased on the observed trajectory patterns, patients who have late-life depression with high baseline depression severity are unlikely to respond after 12 weeks of treatment with venlafaxine XR. However, high baseline depression severity alone may be neither a necessary nor sufficient predictor of treatment nonresponse.TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00892047

show abstract

Trajectories of individual symptoms in remitters versus non-remitters with depression

Cited by 43 publications

References 31 publications

Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials

Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials

Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine

Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults

Contact Info

Product

Resources

About